Favorable clinical course after discontinuation of omalizumab treatment in patients with allergic severe asthma: A real-world clinical practice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Favorable clinical course after discontinuation of omalizumab treatment in patients with allergic severe asthma: A real-world clinical practice

Published:2024-09 Issue:5 Volume:62 Page:762-765
ISSN:2212-5345
Container-title:Respiratory Investigation
language:en
Short-container-title:Respiratory Investigation

Author:

Hamada Satoshi^ORCID,Ogino Eriko,Yasuba Hirotaka

Publisher

Elsevier BV

Reference14 articles.

1. Super-responder and clinical remission in patients with asthma on treatment with single biologic therapy or cycling therapy using dupilumab in a real-world setting;Hamada;Int J Clin Pharmacol Therapeut,2024

2. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry;McDowell;Eur Respir J,2023

3. Asthma patients who stop asthma biologics have a similar risk of asthma exacerbations as those who continue asthma biologics;Jeffery;J Allergy Clin Immunol Pract,2021

4. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control;Molimard;Respir Med,2014

5. Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma;Vennera;Thorax,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3